Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mertens

Showing results (181-190 of 211) with videos related to

Pageof 22
Sort By:
Urologic Oncology|February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology|August 9, 2021
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology|June 9, 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomyN Vasdev, H Zargar, J P Noël, et al.
Urologic Oncology|November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomyAnna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
World Journal of Urology|September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancerSarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
Actas Urologicas Espanolas|March 18, 2026
Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl QuestionnaireJ Caño-Velasco, A Luis-Cardo, J C Moreno-Cortés, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 13, 2019
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort ValidationJudith Wienke, Felicitas Bellutti Enders, Johan Lim, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
European Urology|September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancerHomayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
World Journal of Urology|October 28, 2025
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year studyMario de Angelis, Francesco Pellegrino, Pietro Scilipoti, et al.
Pageof 22

Showing results (181-190 of 211) with videos related to

Sort By:
Pageof 22
Urologic Oncology|February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology|August 9, 2021
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology|June 9, 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomyN Vasdev, H Zargar, J P Noël, et al.
Urologic Oncology|November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomyAnna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
World Journal of Urology|September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancerSarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
Actas Urologicas Espanolas|March 18, 2026
Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl QuestionnaireJ Caño-Velasco, A Luis-Cardo, J C Moreno-Cortés, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 13, 2019
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort ValidationJudith Wienke, Felicitas Bellutti Enders, Johan Lim, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
European Urology|September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancerHomayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
World Journal of Urology|October 28, 2025
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year studyMario de Angelis, Francesco Pellegrino, Pietro Scilipoti, et al.
Pageof 22